U.S. Markets closed

Cesca Therapeutics Inc. to Exhibit at Several Upcoming Cell Therapy Conferences

RANCHO CORDOVA, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca” or the “Company”) (KOOL) today announced that the Company will be exhibiting its full suite of cellular processing solutions, including CAR-TXpress™ for the semi-automated manufacture of CAR-T cell therapies, X-BACS™ for cell isolation and other X-Series™ kits, at the following cell therapy conferences in May:

  • International Society of Cellular Therapy 2018 Annual Meeting

            May 2 – 5, 2018
            Booth: 322
            Palais des congrès de Montréal
            1001, Place Jean-Paul-Riopelle
            Montreal, Canada
            For more information: www.isct2018.com 

  • American Society of Gene and Cell Therapy 2018 Annual Meeting

            May 16 – 19, 2018
            Booth: 417
            Hilton Chicago
            720 South Michigan Avenue
            Chicago, IL 60605
            For more information: www.asgct.org/meetings-workshops/annual-meeting 

  • Phacilitate Automation Special Interest Group 2018

            May 30 – 31, 2018
            The Grove
            Chandler’s Cross,
            Watford WD3 4TG, Hertfordshire
            London, UK
            For more information: www.phacilitateautomation.com 

About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress™ platform that addresses the critical unmet need for better cellular manufacturing and controls for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.

Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
ir@cescatherapeutics.com 

Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
pschwartz@rxir.com